Liraglutide, GLP-1 receptor agonist, for chronic weight loss

References

• Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9945):766.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Novo Nordisk receives FDA approval for Saxenda (liraglutide [rDNA origin] injection) for chronic weight management. 2014 Dec 24. [cited 2016 Mar 3]. Available from: http://press.novonordisk-us.com/News-Releases?item=122801
   Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009;43:1433–1444.
   PubMed Web of Science ®Google Scholar
• Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31:2472–2488.
   PubMed Web of Science ®Google Scholar
• Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract. 2012;97:27–42.
   PubMed Web of Science ®Google Scholar
• Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide1 derivative, in healthy male subjects. Diabetes Care. 2002;25(8):1398–1404.
   PubMed Web of Science ®Google Scholar
• Watson E, Jonker DM, Jacobsen LV, et al. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50(8):886–894.
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68(6):898–905.
   PubMed Web of Science ®Google Scholar
• Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol. 2010;70(6):807–814.
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Flint A, Olsen AK, et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55:657–672.
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once daily human GLP-1 analog, added to a sulphoflurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes (abstract 13-OR). Diabetes. 2008;57:A4.
   Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care. 2009;32:84–90.
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481.
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomised double- blind placebo controlled trial [abstract 898]. Diabetologia. 2008;51:S359.
   Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and sulfonylurea in type 2 diabetes [abstract 536-P]. Diabetes. 2008;57:A536–P.
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Gaal LV, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443–1451.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• Saxenda [package insert]. Plainsboro (NJ): Novo Nordisk; 2015.
   Google Scholar
• Novo Nordisk. Saxenda approved in Europe for the treatment of obesity. 2015 Mar 23. [cited 2016 Mar 3]. Available from: https://www.novonordisk.com/bin/getPDF.1905678.pdf
   Google Scholar
• Ventura J. FDA approves weight-management drug Saxenda. 2014 Dec 23. [cited 2016 Mar 3]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02696148. A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years. [cited 2016 Mar 3]. Available from https://clinicaltrials.gov/ct2/show/NCT02696148?term=liraglutide+AND+obesity&cond=%22Obesity%22&rank=13
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01789086. A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 years. [cited 2016 Mar 3]. Available from https://clinicaltrials.gov/ct2/show/NCT02696148?term=liraglutide+AND+obesity&cond=%22Obesity%22&rank=13
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01557166. Effect of Liraglutide in Obese Subjects with Moderate or Severe Obstructive Sleep Apnoea: SCALE-Sleep Apnoea. [cited 2016 Mar 28]. Available from https://clinicaltrials.gov/ct2/show/NCT01557166?term=liraglutide&cond=”obesity”&rank=12
   Google Scholar
• Clements JN, Shealy KM. Liraglutide: an injectable option for the management of obesity. Ann Pharmacother. 2015;49(8):938–944.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jun 13;375:311–322. Epub ahead of print. doi:10.1056/NEJMoa1603827.
   PubMed Web of Science ®Google Scholar
• Iepsen EW, Lundgren JR, Hartmann B, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100(8):2909–2917.
   PubMed Web of Science ®Google Scholar